Ⅱ型单纯疱疹病毒mRNA疫苗

Search documents
首笔EF账户澳门元ODI落地;中国芯拟10月举办丨横琴财报⑥
2 1 Shi Ji Jing Ji Bao Dao· 2025-07-31 11:47
Group 1: Clinical Trials and Biotechnology - The phase I clinical trial for the type II herpes simplex virus mRNA vaccine developed by Zhuhai Lifanda Biotechnology Co., Ltd. and Changchun Baike Biotechnology Co., Ltd. has commenced, focusing on safety, tolerability, and immunogenicity among participants aged 18 to 55 [1] - Zhuhai Lifanda, established in June 2019, specializes in the development of mRNA drugs targeting infectious diseases, tumors, rare diseases, and other protein deficiency-related conditions [1] Group 2: Financial Services and Cross-Border Investment - The first EF account under the Macao dollar ODI business has been successfully processed by the Hengqin branch of China Construction Bank for Chip Tide (Zhuhai) Technology Co., Ltd., marking a significant milestone in cross-border financial services [2] - As of June 2025, the Hengqin branch has opened 103 EF accounts, becoming the first pilot bank to surpass 100 accounts, with a total fund transfer and foreign exchange volume exceeding 700 million yuan [2] Group 3: Real Estate and Housing Solutions - The "He Yu" rental platform, launched by Hengqin Shenhe Asset Management Co., Ltd., aims to address housing challenges for talent in the Hengqin Guangdong-Macao Deep Cooperation Zone by increasing the supply of high-quality housing [3] - The platform intends to enhance the rental process through technology, ensuring efficient matching between talent and housing resources, and aims to create a community ecosystem for residents [3] Group 4: Pharmaceutical and Traditional Medicine - Guangdong-Macao Pharmaceutical Co., Ltd., the only Chinese and EU GMP certified traditional Chinese medicine manufacturer in the Hengqin Guangdong-Macao Deep Cooperation Zone, has established a comprehensive production and quality management system [4] - As of July 2025, the company has provided production and registration agency services for over 20 types of Macao traditional Chinese medicine products, facilitating the integration of Macao's international platform with Hengqin's production capabilities [4] Group 5: Tourism and Cross-Border Travel - The Hengqin port has seen over 2.08 million inbound and outbound travelers during the summer period, representing a 27.6% increase compared to the same period last year, with 1.28 million from the mainland [5] - The implementation of convenient travel policies, such as "one visa multiple entries," has significantly boosted cross-border tourism products between Hengqin and Macao [6] Group 6: Industry Events and Support Initiatives - The 20th "China Chip" excellent product solicitation event is set to take place on October 29 in the Hengqin Guangdong-Macao Deep Cooperation Zone, with submissions open until August 30 [7] - The event aims to recognize outstanding chip products and enterprises, particularly in the automotive industry and RISC-V ecosystem promotion [7] - The cross-border e-commerce industry support application for the first half of 2025 has been officially launched, encouraging service providers to support e-commerce enterprises with various professional services [8]